Tocagen (TOCA) Moves On B.Riley FBR Initiation with $15.0000 Target; AGILE THERAPEUTICS (AGRX) Has 1.71 Sentiment

May 16, 2018 - By Martha Paddon

Agile Therapeutics, Inc. (NASDAQ:AGRX) Logo

B.Riley FBR sent to clients and investors in a research report that it has begun coverage on Tocagen Inc (TOCA) stock, with a “Buy” rating and a $15.0000 target.

AGILE THERAPEUTICS INC (AGRX) investors sentiment increased to 1.71 in 2017 Q4. It’s up 0.36, from 1.35 in 2017Q3. The ratio has increased, as 29 investment professionals started new or increased stock positions, while 17 trimmed and sold stock positions in AGILE THERAPEUTICS INC. The investment professionals in our database reported: 22.48 million shares, down from 23.16 million shares in 2017Q3. Also, the number of investment professionals holding AGILE THERAPEUTICS INC in top ten stock positions was flat from 4 to 4 for the same number . Sold All: 11 Reduced: 6 Increased: 16 New Position: 13.

The stock decreased 0.53% or $0.05 during the last trading session, reaching $9.45. About 79,607 shares traded. Tocagen Inc. (TOCA) has 0.00% since May 16, 2017 and is . It has underperformed by 11.55% the S&P500.

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. The company has market cap of $188.17 million. The Company’s cancer-selective gene therapy platform is built on retroviral replicating vectors , which are designed to deliver therapeutic genes into the DNA of cancer cells. It currently has negative earnings. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma.

Among 2 analysts covering Tocagen (TOCA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Tocagen has $28 highest and $2400 lowest target. $26’s average target is 175.13% above currents $9.45 stock price. Tocagen had 2 analyst reports since May 9, 2017 according to SRatingsIntel. The firm has “Buy” rating by Stifel Nicolaus given on Monday, July 24.

Analysts await Tocagen Inc. (NASDAQ:TOCA) to report earnings on August, 8. They expect $-0.39 earnings per share, up 30.36% or $0.17 from last year’s $-0.56 per share. After $-0.65 actual earnings per share reported by Tocagen Inc. for the previous quarter, Wall Street now forecasts -40.00% EPS growth.

More notable recent Tocagen Inc. (NASDAQ:TOCA) news were published by: Prnewswire.com which released: “Tocagen to Present Preclinical Data on Anti-PD-L1 Product Candidate Toca 521 at the 2018 Annual Meeting of The …” on May 14, 2018, also Benzinga.com with their article: “The Week Ahead In Biotech: PDUFA Dates, IPOs And More” published on April 20, 2018, Prnewswire.com published: “Tocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 & Toca FC in the Greater …” on April 19, 2018. More interesting news about Tocagen Inc. (NASDAQ:TOCA) were released by: Streetinsider.com and their article: “Tocagen (TOCA) Reports Preliminary Toca 6 Phase 1 Data in Patients with Advanced Solid Tumors” published on April 16, 2018 as well as Prnewswire.com‘s news article titled: “Tocagen to Present Updated Clinical and Preclinical Data at Three Scientific Conferences” with publication date: April 17, 2018.

Proquest Associates Iv Llc holds 18.09% of its portfolio in Agile Therapeutics, Inc. for 5.06 million shares. Caxton Corp owns 1.82 million shares or 5.95% of their US portfolio. Moreover, Aisling Capital Llc has 0.69% invested in the company for 1.30 million shares. The Sweden-based Investor Ab has invested 0.62% in the stock. Perceptive Advisors Llc, a New York-based fund reported 3.38 million shares.

Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. The company has market cap of $91.10 million. The Company’s lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. It currently has negative earnings. The firm is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

Analysts await Agile Therapeutics, Inc. (NASDAQ:AGRX) to report earnings on July, 27. They expect $-0.17 earnings per share, up 34.62% or $0.09 from last year’s $-0.26 per share. After $-0.21 actual earnings per share reported by Agile Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -19.05% EPS growth.

It closed at $2.66 lastly. It is up 11.00% since May 16, 2017 and is downtrending. It has underperformed by 22.55% the S&P500.

Agile Therapeutics, Inc. (NASDAQ:AGRX) Ratings Chart